Insider buying last 90 days
No open-market insider purchases were filed for AVAH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AVAH insider filing, plotted on the chart in Gekko.Open AVAH in Gekko
NASDAQ: AVAH
Aveanna Healthcare (AVAH) Stock Analysis & Forecast
Oct 12 close
$12.21−0.04 (−0.3%)
Gekko Brief
AI summaryOct 12 closeThis week's commentary centers on Aveanna Healthcare's earnings track record and the investment case following its last report. Coverage notes the company's history of beating analyst estimates, with a recent earnings beat prompting renewed scrutiny of the stock. Also noted is the resignation of independent director Steven E. Rodgers, which leaves vacancies on the Audit and Compensation Committees. A Form 4 filing was also released on 12 October, though no further detail on its contents is given.
AVAH closed at $12.21, down 0.3%, sitting just below its 50-day average of $12.50 and well above its 200-day average of $8.93. The stock's one-month return stands at -13.3%, while three-month and six-month returns remain strong at 30.7% and 89.9% respectively. The GekkoIndex reads 62.1, placing the stock in the Accumulation zone. Price sits 8.7% below Gekko Fair Value of $13.37.
Aveanna next reports earnings on 5 November, 24 days away and within a typical 20-trading-day holding window; the prior report on 13 August showed EPS of $0.16 matching estimates, with a 36.1% reaction, and the company has beaten estimates in 7 of the last 8 quarters. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality from this point in the calendar has averaged a 9.9% move over the next 20 trading days across 5 years, rising in 4 of them. Consensus among 9 covering firms stands at 6 buy and 3 hold ratings, with a consensus target of $14.85.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Aveanna Healthcare price vs fair value
Close $12.21200-day averageGekko Fair Value $13.37
Aveanna Healthcare quick facts
- Market cap
- $2.66B
- P/E ratio
- 9.8
- Forward P/E
- 13.3
- EPS, TTM
- $1.26
- Revenue, TTM
- $2.60B
- Profit margin
- 10.6%
- Dividend yield
- —
- Beta
- 1.95
- Volume
- 1.69M avg 3.23M
- 1-year return
- +38.6%
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±12.7%
- 50-day average
- $12.50
- 200-day average
- $8.93
- Next earnings
- Nov 5 before open
- Shares outstanding
- 218.3M
Aveanna Healthcare swing-trade checklist
Aveanna Healthcare scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $12.21 sits between the 50-day ($12.50) and 200-day ($8.93) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
62.1, Accumulation
Reading 62.1 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
8.7% below
Price is 8.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+9.9% on average
From this point in the calendar, the next 20 trading days averaged +9.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Aveanna Healthcare stock chart and price history
Aveanna Healthcare closed at $12.21 on Oct 12, 2026, +38.6% over the past year, inside a 52-week range of $5.93 to $14.71.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.3%
- 3 months
- +30.7%
- 6 months
- +89.9%
- 1 year
- +38.6%
The full AVAH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AVAH in Gekko
Follow Aveanna Healthcare through every session
Put AVAH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AVAH in GekkoFree for 7 days. No credit card required.
About Aveanna Healthcare
Aveanna Healthcare provides home-based medical care across the United States, covering private duty nursing, adult home health and hospice, pediatric therapy, and enteral nutrition supplies. Its services are built around letting patients receive treatment at home rather than in hospitals or other institutional settings, with offerings that range from skilled nursing for medically fragile children to therapy and nutrition support for adults.
The business runs through three segments. Private Duty Services covers nursing for children at home, in schools, and at pediatric day health centers, along with personal care, employer-of-record support, and pediatric physical, occupational, and speech therapy. Home Health & Hospice handles skilled nursing, therapy, social work, and aide services in the home, plus hospice care for patients whose illnesses no longer respond to curative treatment. Medical Solutions delivers enteral nutrition products and other medical supplies to adult and pediatric patients, shipped on a scheduled or as-needed basis.
Aveanna Healthcare was founded in 2016 and is headquartered in Atlanta, Georgia. Its shares are listed on the NASDAQ under the ticker AVAH.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- aveanna.com
Aveanna Healthcare GekkoIndex: the smart money zone
Aveanna Healthcare’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.1, in the Accumulation zone, down 0.6 points over five sessions.
62.1Accumulation
Down 0.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | +7.9% | +29.1% | ||
| Accumulation (current zone) | 208 | +2.6% | +12.0% | ||
| Neutral | 367 | +0.7% | +3.7% | ||
| Distribution | 67 | +1.7% | +1.8% | ||
| Selling | 8 | Too few readings yet | |||
Average AVAH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AVAH price, zone by zone.Track AVAH in Gekko
Is Aveanna Healthcare stock overvalued? Gekko Fair Value
Aveanna Healthcare trades 8.7% below Gekko Fair Value of $13.37, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Aveanna Healthcare shares are worth, recalculated every trading day.
$13.37
Gekko Fair Value, Oct 9, 2026
8.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AVAH in Gekko
Aveanna Healthcare insider and Congress trading
No open-market insider purchases were filed for Aveanna Healthcare, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AVAH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AVAH, plotted on the chart in Gekko.Open AVAH in Gekko
Buybacks
Aveanna Healthcare has been buying back its own shares.
- Bought back, quarter ended Jan 3, 2026
- $4.62M
- As a share of market cap
- 0.17%
From company filings.
Aveanna Healthcare earnings: next date and track record
Aveanna Healthcare reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- $0.21
- Revenue estimate
- $679.5M
7 of 8reports beat the EPS estimate
±23.8%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Aveanna Healthcare Holdings Q2 2026 earnings call: Management (CEO Jeffrey Shaner and CFO Matthew Buckhalter) presented strong Q2 results: revenue $670.5M (+13.7% YoY) and adjusted EBITDA $95.4M (+8% YoY). All three operating divisions (private duty services - PDS, home health & hospice, and medical solutions) grew. Management highlighted improved labor market trends, increased preferred payer mix, and operational efficiencies. They discussed California Medi-Cal rate increase expected to be finalized by end-September and effective Jan 1, 2027, which will enable wage passthrough to attract caregivers and unlock hospital discharges and unmet homecare demand. Family First Homecare acquisition integration is progressing well; prior guidance already reflected its contribution. Management raised 2026 guidance (enhanced guidance) and updated long-term growth outlook (raising long-term organic growth rates for PDS and home health/hospice, and increased M&A contribution). They reiterated target of <3x leverage and 13-14% EBITDA margin (maybe up to 15%). Key strategic priorities: focus on preferred payer alignments, wage passthrough to hire caregivers, M&A (especially in home health), leveraging scale and technology for onboarding/training, and state-level advocacy. Risks discussed include labor market constraints, timing of state rate finalizations, potential macro/state budget constraints, and that rate increases take time to translate to volume. No explicit quantitative 2027 guidance provided on revenue/EBITDA.
- Guidance
- Enhanced 2026 guidance was announced (management said they raised revenue and EBITDA guidance for 2026), and long-term growth outlook was updated (PDS long-term organic growth raised to ~5-6% versus prior 3-5%; home health and hospice raised to 8-10% vs prior 5-7%; long-term revenue uplift of ~150 bps at corporate level from 4.6% to 6.1% mentioned). Management reiterated 13-14% EBITDA margin target and sub-3x leverage target. No specific 2027 numeric guidance provided; California rate expected effective Jan 1, 2027, with wage passthrough starting Oct-Nov 2026. For details: PDS preferred payer mix expected to be mid-to-high 60s in 2026 and mid-80s (3-5 years) long-term. Family First Homecare's contribution had been previously included.
- Risks flagged
- Risks noted: labor market / caregiver shortages and wage inflation (primary gating factor to growth); timing risk around state rate schedules (California Medi-Cal rate finalization timing); state budget constraints and OBBBA (federal/state policy) uncertainties; integration risks for acquisitions (EMR/back office transitions); potential temporary leverage increases from acquisitions though management expects deleveraging; payor negotiation/timing variability.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | $0.16 est $0.16 | $670.5M est $638.6M | +36.1% |
| May 14, 2026 | $0.18 est $0.13 | $647.9M est $613.2M | +14.0% |
| Mar 19, 2026 | $0.17 est $0.13 | $662.5M est $643.0M | −5.6% |
| Nov 6, 2025 | $0.15 est $0.08 | — | −5.0% |
| Aug 7, 2025 | $0.18 est $0.04 | — | +57.8% |
| May 8, 2025 | $0.10 est $0.00 | $559.2M est $527.3M | +12.0% |
| Mar 13, 2025 | $0.05 est $0.00 | $519.9M est $516.2M | +38.8% |
| Nov 7, 2024 | $0.02 est −$0.01 | — | +21.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Aveanna Healthcare stock forecast and analyst price targets
Analysts’ average 12-month price target for Aveanna Healthcare is $14.85, +21.6% from the last close, from 9 firms rating the stock in the last 90 days.
$14.85consensus 12-month target, +21.6% from the last close
Now $12.21Avg $14.85
Low $13High $16
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Barclays | $15 | +22.9% |
| Sep 28 | Raymond James | $15 | +22.9% |
| Sep 25 | Barclays | $15 | +22.9% |
| Sep 14 | J.P. Morgan | $15 | +22.9% |
| Aug 28 | Barclays | $15 | +22.9% |
+12.0%average 20-day move after past Accumulation readings
+9.9%average move over the next 20 trading days in the last 5 years
±3.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Aveanna Healthcare seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Aveanna Healthcare averaged +9.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +9.1% | 4 of 5 |
| Next 10 trading days | +6.0% | 4 of 5 |
| Next 15 trading days | +9.8% | 5 of 5 |
| Next 20 trading days | +9.9% | 4 of 5 |
| Next 30 trading days | +16.2% | 4 of 5 |
For scale, AVAH’s typical 20-trading-day move in either direction is about 12.7%.
Aveanna Healthcare market cap and key statistics
Aveanna Healthcare’s market cap is $2.66B, with a P/E ratio of 9.8 and revenue of $2.60B over the last twelve months.
Valuation
- Market cap
- $2.66B
- P/E ratio
- 9.8
- Forward P/E
- 13.3
- EPS, TTM
- $1.26
- Gekko Fair Value
- $13.37
Trading
- Volume
- 1.69M
- Avg volume, 20 days
- 3.23M
- 52-week high
- $14.71
- 52-week low
- $5.93
- Shares outstanding
- 218.3M
Financials
- Revenue, TTM
- $2.60B
- Profit margin
- 10.6%
- Return on equity
- 198.6%
- Quarterly earnings growth, YoY
- +38.5%
Risk and income
- Beta
- 1.95
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±12.7%
Aveanna Healthcare stock news this week
4 headlines about Aveanna Healthcare from the past week, newest first, each linking to the publisher.
- Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?Zacks Investment Research, Oct 12
- Form 4 Aveanna Healthcare Holdings Inc For: 12 October By Investing.comInvesting.com India, Oct 12
- Is Earnings Beat Altering The Investment Case For Aveanna Healthcare Holdings (AVAH)?Simply Wall Street, Oct 11
- Will Aveanna (AVAH) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research, Oct 9
Aveanna Healthcare peers
Aveanna Healthcare’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Aveanna Healthcare stock FAQ
What is Aveanna Healthcare’s market cap?
Aveanna Healthcare’s market cap is $2.66B at the Oct 12, 2026 close of $12.21, with 218.3M shares outstanding. The shares trade on a P/E ratio of 9.8.
What is the Aveanna Healthcare stock forecast?
The consensus analyst 12-month price target for Aveanna Healthcare is $14.85, +21.6% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Aveanna Healthcare stock overvalued or undervalued?
On Gekko’s estimate Aveanna Healthcare is undervalued: the Oct 12, 2026 close of $12.21 is 8.7% below Gekko Fair Value of $13.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Aveanna Healthcare report earnings next?
Aveanna Healthcare is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of $0.21 per share on revenue of $679.5M. Aveanna Healthcare beat the earnings estimate in 7 of its last 8 reports, moving 23.8% on average across the report.
What is Aveanna Healthcare’s 52-week high and low?
Aveanna Healthcare’s 52-week high is $14.71 and its 52-week low is $5.93; it closed at $12.21 on Oct 12, 2026, +38.6% over the past year.
Is Aveanna Healthcare stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Aveanna Healthcare the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.